Uncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications. 


GlaxoSmithKline said it will pay $75 per share in cash to take over US oncology player Tesaro, whose FDA-approved DNA repair blocker nirparib (Zejula) made only US$166m in sales in Q1-3/2018.

Janssen affiliate Cilag GmbH International has licenced argenx’ anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.

Forbion, a European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1st January 2019.

Swiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.

UK-based biotech startup Fluidic Analytics has raised €27m for its proteomics platform. The financing round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus Capital Partners. 

Diagnostic results must be readily available to diagnose critically ill patients in emergency settings and at ICUs. So far, diagnostic blood tests, which demonstrably could help emergency meds recognise residual congestion in heart failure, septic shock, or acute kidney injury before patients reach critical condition, have not been available in the automated format required at ICUs. After Sphingotec acquired Nexus IB-10 POC testing platform in May, investors wait in line.

French Carbios SA has signed a letter of intent with PVC giant Kem One to implement a demonstration plant to provide proof of concept of Carbios‘ groundbreaking enzymatic PET depolymerisation technology.

German Adrenomed AG has bagged €24m in equity financing from HBM Healthcare Investments and Wellington Partners.

Researchers at Genentech have locally blocked lung inflammation in a mouse model for asthma by administration of an inhalable JAK1 inhibitor.